

C1
Concl

composition comprises a unit dose of *Bacillus anthracis* anthrax protective antigen and said full length protein bound to an anthrax protective antigen binding protein, wherein the molar ratio of protective antigen to the full length protein bound to the anthrax protective antigen binding protein is greater than one, and wherein the anthrax protective antigen binding protein comprises at least about the first 250 amino acid residues of the lethal factor of *Bacillus anthracis* and less than all of the amino acid residues of the lethal factor.

REMARKS

Claims 1-6 are pending in the present application. Appendix A shows the "Version with markings to show changes made." Appendix B provides the pending claims for the Examiner's convenience. As requested by the Examiner, Applicants have now provided a "clean copy" of claim 1 as amended. Applicants therefore request entry of the amendment.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

Klimpel et al.
Application No.: 09/853,530
Page 3

PATENT

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Annette S. Parent". The signature is fluid and cursive, with the first name being the most prominent.

Annette S. Parent
Reg. No. 42,058

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
ASP:dk
SF 1388957 v1

APPENDIX A

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

1. (twice amended) A composition capable of inducing an immune response in a mammal to cytotoxic T cell epitopes of a full length protein wherein the composition comprises a unit dose of [an] *Bacillus anthracis* anthrax protective antigen and said full length protein bound to an anthrax protective antigen binding protein, wherein the molar ratio of protective antigen to the full length protein bound to the anthrax protective antigen binding protein is greater than one, and wherein the anthrax protective antigen binding protein comprises at least about the first 250 amino acid residues of the lethal factor of *Bacillus anthracis* and less than all of the amino acid residues of the lethal factor.

APPENDIX B
PENDING CLAIMS

1. (twice amended) A composition capable of inducing an immune response in a mammal to cytotoxic T cell epitopes of a full length protein wherein the composition comprises a unit dose of *Bacillus anthracis* anthrax protective antigen and said full length protein bound to an anthrax protective antigen binding protein, wherein the molar ratio of protective antigen to the full length protein bound to the anthrax protective antigen binding protein is greater than one, and wherein the anthrax protective antigen binding protein comprises at least about the first 250 amino acid residues of the lethal factor of *Bacillus anthracis* and less than all of the amino acid residues of the lethal factor.

2. (previously once amended) The composition of claim 1 wherein the protective antigen is a processed protective antigen.

3. (previously once amended) The composition of claim 1 wherein the composition is sterile.

4. (previously once amended) The composition of claim 1 wherein the composition further comprises physiologically compatible salts.

5. (previously once amended) The composition of claim 4 wherein the composition is in an aqueous solution of physiologically compatible salts.

6. (previously once amended) The composition of claim 1 wherein the anthrax protective antigen binding protein is the lethal factor of *Bacillus anthracis*.